Eli Lilly: Olumiant's promising results against alopecia
(CercleFinance.com) - Eli Lilly and Incyte today announced detailed results from two pivotal Phase 3 trials showing that single-dose Olumiant (baricitinib) achieved significant hair regrowth as early as 24 weeks in adults with severe alopecia (baldness).
In both studies, a greater proportion of patients taking Olumiant (4mg) achieved full regrowth or regrowth with minimal deviations in eyebrow and eyelash coverage at 36 weeks, compared to those taking placebo.
The results will be presented virtually at the 30th Congress of the European Academy of Dermatology and Venereology (EADV), which is until 2 October.
Olumiant has already received Breakthrough Therapy designation from the FDA for the treatment of alopecia, and Eli Lilly now plans to apply to the FDA by the end of the year to submit a New Drug Application for Olumiant as a treatment for alopecia.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
In both studies, a greater proportion of patients taking Olumiant (4mg) achieved full regrowth or regrowth with minimal deviations in eyebrow and eyelash coverage at 36 weeks, compared to those taking placebo.
The results will be presented virtually at the 30th Congress of the European Academy of Dermatology and Venereology (EADV), which is until 2 October.
Olumiant has already received Breakthrough Therapy designation from the FDA for the treatment of alopecia, and Eli Lilly now plans to apply to the FDA by the end of the year to submit a New Drug Application for Olumiant as a treatment for alopecia.
Copyright (c) 2021 CercleFinance.com. All rights reserved.